PDF(Pubmed)
Abstract：
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can progress into a severe form of acute lung injury. The cosignaling receptor cluster of differentiation 48 (CD48) exists in membrane-bound (mCD48) and soluble (sCD48) forms and has been reported to be implicated in antiviral immunity and dysregulated in several inflammatory conditions. Therefore, CD48 dysregulation may be a putative feature in COVID-19-associated inflammation that deserves consideration.
To analyze CD48 expression in lung autopsies and peripheral blood leukocytes and sera of patients with COVID-19. The expression of the CD48 ligand 2B4 on the membrane of peripheral blood leukocytes was also assessed.
Twenty-eight lung tissue samples obtained from COVID-19 autopsies were assessed for CD48 expression using gene expression profiling immunohistochemistry (HTG autoimmune panel). Peripheral whole blood was collected from 111 patients with COVID-19, and the expression of mCD48 and of membrane-bound 2B4 was analyzed by flow cytometry. Serum levels of sCD48 were assessed by enzyme-linked immunosorbent assay.
Lung tissue of patients with COVID-19 showed increased CD48 messenger RNA expression and infiltration of CD48+ lymphocytes. In the peripheral blood, mCD48 was considerably increased on all evaluated cell types. In addition, sCD48 levels were significantly higher in patients with COVID-19, independently of disease severity.
Considering the changes of mCD48 and sCD48, a role for CD48 in COVID-19 can be assumed and needs to be further investigated.
To analyze CD48 expression in lung autopsies and peripheral blood leukocytes and sera of patients with COVID-19. The expression of the CD48 ligand 2B4 on the membrane of peripheral blood leukocytes was also assessed.
Twenty-eight lung tissue samples obtained from COVID-19 autopsies were assessed for CD48 expression using gene expression profiling immunohistochemistry (HTG autoimmune panel). Peripheral whole blood was collected from 111 patients with COVID-19, and the expression of mCD48 and of membrane-bound 2B4 was analyzed by flow cytometry. Serum levels of sCD48 were assessed by enzyme-linked immunosorbent assay.
Lung tissue of patients with COVID-19 showed increased CD48 messenger RNA expression and infiltration of CD48+ lymphocytes. In the peripheral blood, mCD48 was considerably increased on all evaluated cell types. In addition, sCD48 levels were significantly higher in patients with COVID-19, independently of disease severity.
Considering the changes of mCD48 and sCD48, a role for CD48 in COVID-19 can be assumed and needs to be further investigated.
摘要：
背景：2019年冠状病毒病（COVID-19），由严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）引起，可以发展成严重的急性肺损伤。共信号传导分化受体簇48(CD48)以膜结合(mCD48)和可溶性(sCD48)形式存在,并且已经报道与抗病毒免疫有关,并且在几种炎性病症中失调。因此,CD48失调可能是COVID-19相关炎症的一个假定特征，值得考虑。
目的：分析COVID-19患者肺部尸检、外周血白细胞和血清中CD48的表达。还评估了CD48配体2B4在外周血白细胞膜上的表达。
方法：使用基因表达谱免疫组织化学（HTG自身免疫组）评估了从COVID-19尸检中获得的28个肺组织样本的CD48表达。收集111例COVID-19患者的外周血，并通过流式细胞术分析mCD48和膜结合2B4的表达。通过酶联免疫吸附试验评估血清sCD48水平。
结果：COVID-19患者肺组织CD48信使RNA表达增加，CD48+淋巴细胞浸润。在外周血中，mCD48在所有评估的细胞类型上显著增加。此外,COVID-19患者的sCD48水平明显更高，与疾病严重程度无关。
结论：考虑到mCD48和sCD48的变化，可以假设CD48在COVID-19中的作用，需要进一步研究。
目的：分析COVID-19患者肺部尸检、外周血白细胞和血清中CD48的表达。还评估了CD48配体2B4在外周血白细胞膜上的表达。
方法：使用基因表达谱免疫组织化学（HTG自身免疫组）评估了从COVID-19尸检中获得的28个肺组织样本的CD48表达。收集111例COVID-19患者的外周血，并通过流式细胞术分析mCD48和膜结合2B4的表达。通过酶联免疫吸附试验评估血清sCD48水平。
结果：COVID-19患者肺组织CD48信使RNA表达增加，CD48+淋巴细胞浸润。在外周血中，mCD48在所有评估的细胞类型上显著增加。此外,COVID-19患者的sCD48水平明显更高，与疾病严重程度无关。
结论：考虑到mCD48和sCD48的变化，可以假设CD48在COVID-19中的作用，需要进一步研究。
